Search results
Showing 46 to 56 of 56 results for gynaecological cancer
Biographies and registered interests for members of the Technology Appraisal Committee C
Biographies and registered interests for members of the Technology Appraisal Committee C
This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.
View quality statements for QS73Show all sections
Sections for QS73
- List of quality statements
- Quality statement 1: Lifestyle advice
- Quality statement 2: Referral for specialist consultation
- Quality statement 3: Counselling
- Quality statement 4: Semen analysis
- Quality statement 5: IVF for women, trans men and non-binary people with female reproductive organs aged under 40 years
- Quality statement 6: IVF for women, trans men and non-binary people with female reproductive organs aged 40 or 41 years
- Quality statement 7: Intracytoplasmic sperm injection
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Discontinued Reference number: GID-TAG332
Discontinued Reference number: GID-TAG444
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
NICE approves first immunotherapy combination for endometrial cancer
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
risk of ovarian cancer Podcasts 03 April 2024 Listen About this episode We talk to Ranjit Manchanda, professor of...